Entia Biosciences Overview
Entia Biosciences (ERGO) has a ROE of 74.88%, above the sector sector average of 11.75%.
Get informed when a big investor buys or sells
+ Follow74.88%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Entia Biosciences posts a ROE of 74.88%. That is above the sector sector average of 11.75%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For its sector stocks, a ROE near 11.75% is typical. Entia Biosciences's 74.88% is higher that level. That is roughly 537.1% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Entia Biosciences's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 74.88%; use YoY and peer views to separate noise from signal.
Context for ERGO's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 11.75%), and (3) consistency with growth and profitability. This page covers the first two; Entia Biosciences's other metric pages and overview cover the third.
